Reduced bone mineral density in HIV-infected patients: prevalence and associated factors

Cazanave, Charlesa; Dupon, Michela; Lavignolle-Aurillac, Valéried; Barthe, Nicoleb; Lawson-Ayayi, Sylvied,g; Mehsen, Nadiac; Mercié, Patrickd,e; Morlat, Philliped,f; Thiébaut, Rodolphed; Dabis, Françoisd,g; for the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine

doi: 10.1097/QAD.0b013e3282f423dd
Clinical Science

Background: There is a high prevalence of bone demineralization among HIV-infected patients but mechanisms of alteration of bone turnover are still unclear and it is thought to be multifactorial.

Methods: A cross-sectional survey of 492 HIV-infected patients within the Aquitaine cohort estimated the prevalence of osteoporosis/osteopenia and investigated associated factors. Bone mineral density of total body, lumbar spine and femoral neck was measured by dual-energy X-ray absorptiometry. Multivariable analyses of the association with HIV disease status, treatment and anthropometric parameters were stratified according to gender.

Results: Median age was 43 years (interquartile range, 38–50); 73% were male; 19.7% patients had reached AIDS, 93.1% were treated with HAART; and 28.5% had lipodystrophy. Based on World Health Organization criteria, osteopenia was diagnosed in 54.6% of men [95% confidence interval (CI), 49.4–59.7) and 51.1% of women (95% CI, 42.6–59.6) and osteoporosis in 33.7% of men (95% CI, 28.8–38.6) and 8.3% of women (95% CI, 3.6–13.9). Using a polytomous logistic regression, older age, homosexual transmission group, low body mass index and low HIV plasma viral load were associated with the diagnosis of bone abnormalities in men, whereas older age and low CD4 lymphocyte count nadir were independently associated with osteoporosis/osteopenia in women. The use of HAART was not related to osteoporosis after adjustment (P = 0.58).

Conclusions: This cohort-based survey showed a high prevalence of osteopenia and osteoporosis of multifactorial origin. Mechanisms and consequences of these bone disorders need to be investigated.

Author Information

From the aFédération de Maladies Infectieuses et Tropicales, France

bService de Médecine Nucléaire, France

cService de Rhumatologie, Hôpital Pellegrin, France

dINSERM U593, ISPED, Université Victor Segalen, France

eService de Médecine Interne et Maladies Tropicales, France

fService de Médecine Interne et Maladies Infectieuses, Hôpital Saint-André, France

gCentre d'Information et de Soins de l'Immunodéficience Humaine, Bordeaux, France.

Received 12 March, 2007

Revised 31 August, 2007

Accepted 5 November, 2007

Correspondence to Dr C. Cazanave, Fédération de Maladies Infectieuses et Tropicales, Hôpital Pellegrin, Place A, Raba-Léon, 33076 Bordeaux cedex, France. E-mail:

© 2008 Lippincott Williams & Wilkins, Inc.